Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma

Published:2005-02 Issue: Volume:32 Page:36-43
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Marcus Robert

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference28 articles.

1. SEER Cancer Statistics Review, 1973–1999;Ries,2002

2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma;Fisher;N Engl J Med,1993

3. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas;Solal-Celigny;J Clin Oncol,1998

4. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden;Colombat;Blood,2001

5. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin’s lymphoma;Hainsworth;Blood,2000

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioimmunotherapy;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

2. Introduction of Carbonyl Groups into Antibodies;Molecules;2023-12-01

3. Commercial and business aspects of alpha radioligand therapeutics;Frontiers in Medicine;2023-02-02

4. Siderocalin fusion proteins enable a new ⁸⁶Y/⁹⁰Y theranostic approach;RSC Chemical Biology;2023

5. Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging;Handbook of Cancer and Immunology;2023